drug adverse effects of alkylating agents

Adverse effects

• increased incidence of acute myelocytic leukemia (AML)
  • often preceded by myelodysplastic syndrome
  • peak incidence 4-6 years after alkylating agent therapy
• non-random cytogenetic abnormalities
  • chromosome 7 deletions
  • trisomy 8

More general terms

• drug adverse effect(s)